Form 4: IOVA Executive Reports Stock Vesting and Tax Withholding

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC., reported the vesting of 5,469 Restricted Stock Units (RSUs) and the subsequent withholding of 2,508 shares for tax purposes on June 1, 2026.

Summary

• Raj K. Puri, Chief Regulatory Officer at IOVANCE BIOTHERAPEUTICS, INC., reported transactions on June 1, 2026.
• 5,469 Restricted Stock Units (RSUs) vested on this date.
• As part of the vesting, 2,508 shares of common stock were withheld by the issuer to cover mandatory tax withholding requirements.
• Following these transactions, Mr. Puri beneficially owns 242,191 shares of common stock.
• The remaining RSUs are scheduled to vest in equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine event of equity vesting and tax settlement for an executive, with no indication of significant positive or negative developments for the company.

Positives

• Vesting of 5,469 RSUs indicates continued equity-based compensation and potential alignment of executive interests with shareholder value.
• The remaining RSUs will vest quarterly, suggesting a structured and ongoing incentive plan.

Negatives

• 2,508 shares were withheld for tax purposes, reducing the immediate net shares received by the executive.
• The withholding of shares for taxes represents a reduction in the executive's direct holdings.

Future Outlook

The filing indicates that remaining RSUs will vest in equal quarterly installments, suggesting a continued vesting schedule for the executive.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, including the vesting of equity awards and associated tax implications, which are common practices in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The transaction reflects standard executive compensation practices and does not immediately suggest a change in insider holdings that would significantly impact share price, though it confirms continued executive participation in equity.

Next Steps

• Continued quarterly vesting of remaining RSUs for Raj K. Puri.

Key Dates

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Form 4, SEC Filing, Stock Vesting, Restricted Stock Units, RSUs, Tax Withholding, Beneficial Ownership, Executive Compensation